Eton Pharmaceuticals (NASDAQ:ETON) Stock Price Expected to Rise, Craig Hallum Analyst Says

Eton Pharmaceuticals (NASDAQ:ETON) had its target price upped by equities research analysts at Craig Hallum from $26.00 to $28.00 in a research report issued on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Craig Hallum’s target price points to a potential upside of 42.13% from the stock’s current price.

ETON has been the subject of several other reports. HC Wainwright reaffirmed a “buy” rating and issued a $33.00 price target on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th. B. Riley reaffirmed a “buy” rating and issued a $24.00 price target (up from $21.00) on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th.

Eton Pharmaceuticals Stock Performance

ETON opened at $19.70 on Wednesday. The company has a 50-day moving average of $14.72 and a 200-day moving average of $13.82. The company has a market capitalization of $528.31 million, a P/E ratio of -89.55 and a beta of 1.22. Eton Pharmaceuticals has a 1-year low of $3.18 and a 1-year high of $21.48.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings results on Tuesday, May 13th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.02). Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. The business had revenue of $17.28 million during the quarter, compared to analyst estimates of $14.33 million. As a group, sell-side analysts expect that Eton Pharmaceuticals will post -0.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ETON. AlphaQuest LLC acquired a new position in Eton Pharmaceuticals during the 1st quarter valued at about $53,000. Tower Research Capital LLC TRC acquired a new position in Eton Pharmaceuticals during the 4th quarter valued at about $86,000. Jane Street Group LLC acquired a new position in Eton Pharmaceuticals during the 3rd quarter valued at about $90,000. Quantbot Technologies LP acquired a new position in Eton Pharmaceuticals during the 1st quarter valued at about $101,000. Finally, Jefferies Financial Group Inc. acquired a new position in Eton Pharmaceuticals during the 4th quarter valued at about $133,000. 27.86% of the stock is owned by institutional investors and hedge funds.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.